Glenmark Pharmaceuticals Ltd. on Tuesday, November 4, said its US-based arm will launch the 8.4% Sodium Bicarbonate Injection USP, which is recommended for controlling metabolic acidosis, a condition caused by excess acid production in the body.

The injection, available in a 50 mEq/50 mL (1 mEq/mL) single-dose vial, is bioequivalent and therapeutically equivalent to Abbott Laboratories’ reference listed drug, the company said in an exchange filing.

Glenmark said it will begin distributing the product in November 2025.

According to IQVIA, sales data for the 12 months ending August 2025, the market for 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) achieved annual sales of approximately $63.8 million.

Sodium Bicarbonate Injection is used to treat metabolic acidosis, a condit

See Full Page